Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,907 shares of the company’s stock after selling 786 shares during the quarter. Hancock Whitney Corp’s holdings in Medpace were worth $19,731,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Rise Advisors LLC acquired a new stake in shares of Medpace during the first quarter worth about $27,000. Mather Group LLC. purchased a new position in Medpace during the 1st quarter worth approximately $28,000. Fidelis Capital Partners LLC purchased a new position in Medpace during the 1st quarter worth approximately $31,000. J.Safra Asset Management Corp increased its position in Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares during the period. Finally, DT Investment Partners LLC purchased a new stake in Medpace in the second quarter valued at approximately $41,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Down 0.9 %

NASDAQ MEDP opened at $365.70 on Friday. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77. The firm has a 50-day moving average price of $378.15 and a 200 day moving average price of $392.02. The stock has a market capitalization of $11.33 billion, a P/E ratio of 37.28, a P/E/G ratio of 1.74 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period in the prior year, the business posted $1.93 EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, equities research analysts expect that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Robert W. Baird lowered their target price on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating on the stock in a research report on Friday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. Guggenheim decreased their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Mizuho initiated coverage on Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Medpace currently has a consensus rating of “Moderate Buy” and an average target price of $420.88.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.